- Home
- ILAG vs PSTV Comparison
ILAG vs PSTV Comparison
Compare ILAG & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- PSTV
- Stock Information
- Founded
- ILAG 1981
- PSTV 1996
- Country
- ILAG Hong Kong
- PSTV United States
- Employees
- ILAG N/A
- PSTV N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- PSTV Medical/Dental Instruments
- Sector
- ILAG Consumer Discretionary
- PSTV Health Care
- Exchange
- ILAG Nasdaq
- PSTV Nasdaq
- Market Cap
- ILAG 18.4M
- PSTV 9.4M
- IPO Year
- ILAG 2022
- PSTV N/A
- Fundamental
- Price
- ILAG $0.98
- PSTV $1.41
- Analyst Decision
- ILAG
- PSTV Strong Buy
- Analyst Count
- ILAG 0
- PSTV 2
- Target Price
- ILAG N/A
- PSTV $14.00
- AVG Volume (30 Days)
- ILAG 47.1K
- PSTV 84.6K
- Earning Date
- ILAG 11-29-2024
- PSTV 10-29-2024
- Dividend Yield
- ILAG N/A
- PSTV N/A
- EPS Growth
- ILAG N/A
- PSTV N/A
- EPS
- ILAG N/A
- PSTV N/A
- Revenue
- ILAG $6,443,357.00
- PSTV $5,509,000.00
- Revenue This Year
- ILAG N/A
- PSTV $11.13
- Revenue Next Year
- ILAG N/A
- PSTV N/A
- P/E Ratio
- ILAG N/A
- PSTV N/A
- Revenue Growth
- ILAG N/A
- PSTV 113.20
- 52 Week Low
- ILAG $0.33
- PSTV $0.97
- 52 Week High
- ILAG $1.35
- PSTV $2.78
- Technical
- Relative Strength Index (RSI)
- ILAG 44.56
- PSTV 46.79
- Support Level
- ILAG $0.97
- PSTV $1.20
- Resistance Level
- ILAG $1.06
- PSTV $1.45
- Average True Range (ATR)
- ILAG 0.06
- PSTV 0.10
- MACD
- ILAG -0.01
- PSTV 0.01
- Stochastic Oscillator
- ILAG 16.32
- PSTV 57.37
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).